Home > Boards > US OTC > Biotechs >

Sinobiopharma, Inc. (fka SNBP)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/25/2019 2:39:36 PM - Followers: 17 - Board type: Free - Posts Today: 0

Forward split occurred on July 29th, 2008....50 to 1 ratio

  • Estimated Market Cap

    25.87 million as of 01/20/2011 (By Quotemedia )
  • Share structure, O/S

    117,587,608 as of  01/20/2011 (By Quotemedia)  ......an increase of 17.6 million(Approx) from split  for compensation for itellectual-propertys and services.

  • A/S = 2,500,000,000

  • Subsidary, Dongying BVI also manufactors pharmacuticals. Aquired in Sept. 2008.

After a distinguished 20-year medical career in the U.S. that saw him become the Principal Scientist at Bayer's Pharmaceutical Division Research Centre in New Haven, CT, Dr. Lequn Huang returned to his native China to become founding Chair of Dong Ying Pharmaceutical Co. Ltd. in 2004.

He proceeded to recruit R&D and management teams to accelerate the growth of Dong Ying into a premier developer and manufacturer of innovative pharmaceuticals for the Chinese domestic and international markets.

Headquarters and a 30,000 sq. meter SFDA GMP-certified production facilities are located in the Nantong Economic and Technology Development Zone, which qualifies Sinobiopharma for extensive tax benefits. R&D labs are located in Nanjing, a major R&D centre with several universities and research institutes. A nationwide distribution network enables Sinobiopharma to market its products in every major city in China.

Demand for Flagship product expected to increase. Cisatracurium Besylate (skeletal-muscle relaxant) produced

by SNBP, requires no refidgeration...unlike any of the other manufactors products.

Dr. Lee Huang, "The market has shown a strong need for our flagship product, KuTai-(cisatracurium b.)

and the sales increases from this product are expected to continue for the next 2 years."

Production of KuTai was temporarily halted to upgrade the equipment.

These upgrade were done to facilitate the expected increases in orders, and to provide economies of

scale. Production of cisatracurium besylate at the Dongying facility was uninterupted.


SNBP manufactoring site now able to meet demands for it's products in the forseeable future.

Current output could be doubled at anytime without the need for additional expenditures for new equiptment.


Financial highlights include:

2010 fiscal year

Total revenue increased 101% in 2010, to approximately $7.7 million-- compared to the $3.9 of the 2009 fiscal year ending May 31st.

Gross margin increased 142% from the prior year.

Net income increased $ 2.9 million. (As opposed to 2009's loss of $2.2 million while the manufactoring facility was expanded.)


         Sales revenue increased to $1,902,376 for the six months ended November 30, 2008 from $583,748 in the corresponding period in 2007.

  • Gross profit increased to $1,223,180 (64% of sales revenue) from $116,009 (20% of revenue).
  • Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate., a skeletal muscle relaxant. Sales of this product increased to $1,756,798 in the six months ended November 30, 2008 from $505,331 in the six months ended November 30, 2007.
  • Operating expenses for the six months ended November 30, 2008 were $2,115,788, as compared to $366,833 for the six months ended November 30, 2007. The most significant category of expenses was stock-based compensation of $972,375 in the six months ended November 30, 2008 compared to $nil in the same period in 2007, as the Company granted stock options to various directors, management, employees and consultants upon completing the reverse acquisition and effectively taking the Dongying companies public.
  • The second most significant expense category is professional fees, which have increased to $290,109 form $30,036 in the same period of the previous year. The main reason for the increase is the reverse acquisition, which required a substantial amount of legal, accounting and audit work to bring the Chinese companies up to U.S. financial reporting standards and to advise on and document the legal agreements. 

    Link to Harbinger research, buy reccomendation stating company is undervalued for it's position.



#400   Rob Sargent how are you managing this shell laraz5 11/25/19 02:39:36 PM
#399   Do not allow this fraud to continue CEO's laraz5 11/21/19 10:13:21 AM
#398   Mr. Sargent can you address the manipulation in laraz5 10/04/19 03:37:40 PM
#397   Since the merger-talk, this things bottom dropped out. backtrax 11/16/11 10:06:40 AM
#396   http://stockcharts.com/h-sc/ui?s=SNBP&p=D&b=5&g=0&id=p19286494216 Lockman 09/27/11 09:06:18 PM
#395   SNBP filed form 15, talk of possible merger backtrax 09/01/11 03:18:47 PM
#394   No transactions today? backtrax 08/05/11 10:43:53 AM
#393   What I don't see, is any indications the backtrax 07/29/11 11:45:20 AM
#392   I can understand PPL becoming impatient, so little backtrax 07/29/11 11:41:08 AM
#391   No action today, seller/sellers R out? backtrax 07/29/11 11:39:39 AM
#390   Some retail bailing out at bargan-prices. When the backtrax 07/28/11 03:42:38 PM
#389   Yawn!!!....tracking this stock is like watching paint dry. olivernoyes 05/21/11 02:53:07 PM
#388   A tiny 8K filing, about resignation of independant director. backtrax 03/28/11 01:33:25 PM
#387   Second close-in-a-row, at .33 backtrax 03/09/11 04:15:30 PM
#386   I obviously need to start paying attention to drkazmd65 03/08/11 04:48:41 PM
#385   Closed today at .33 on low volume. Slowly backtrax 03/08/11 04:11:19 PM
#384   Agreed. Good to see the share price drkazmd65 03/04/11 04:43:41 PM
#383   Good close! Best in a long time. .31 backtrax 03/04/11 04:04:20 PM
#382   Just above .295 has been resistance for quite backtrax 03/04/11 01:55:31 PM
#381   I would just like to see it edge drkazmd65 03/04/11 01:52:46 PM
#380   Anybody want to sell some to keep it backtrax 03/04/11 12:19:15 PM
#379   Not alot going on, I admit....but someone did backtrax 03/04/11 11:42:28 AM
#378   Nobody ever posts here, so nothing to read. olivernoyes 03/01/11 03:33:03 PM
#377   Apparently - has been kind of quiet in drkazmd65 03/01/11 10:11:13 AM
#376   Agreed - it looked like a one-tme, if drkazmd65 01/24/11 11:56:21 AM
#375   Not pretty by any means but it was GorillaGorilla 01/23/11 08:53:26 AM
#374   10Q released Jan 19th. It doesn't look pretty... BigOnChina 01/22/11 08:23:31 PM
#373   What was the report? Link? Was drkazmd65 01/22/11 05:29:59 PM
#372   Ibox has been updated, O/S and market caps backtrax 01/20/11 01:03:16 PM
#371   Harbinger research continues in it's "Buy" reccomendation. backtrax 01/20/11 12:43:48 PM
#370   I bailed as well right after I saw BigOnChina 01/19/11 02:05:10 PM
#369   Good luck to those that stay & sorry pappy 01/19/11 01:43:49 PM
#368   Good to see .30 on a friday before backtrax 01/14/11 02:21:28 PM
#367   Thanks for the heads up pappy on SNBP Huggy Bear 01/08/11 02:27:06 PM
#366   Yup, I was aware they are coming. I backtrax 01/07/11 01:24:56 PM
#365   Remember earnings are due Jan. 15th. pappy 01/07/11 01:18:32 PM
#364   .30 back, did wake up a bit. Lets backtrax 01/07/11 01:00:36 PM
#363   New Year 1st post...someone kick snbp and wake backtrax 01/05/11 08:46:47 AM
#362   Nice to see the buying continue again today. pappy 11/30/10 07:20:18 PM
#361   YW, and thanks back. backtrax 11/24/10 01:27:29 PM
#360   Thank you. pappy 11/24/10 12:18:42 PM
#359   Hope everyone has a great Thanksgiving tomorrow! backtrax 11/24/10 11:39:41 AM
#358   It's an odd stock. It's not the first GorillaGorilla 11/23/10 02:19:48 PM
#357   In the 1st hour of trading today blocks pappy 11/23/10 11:06:04 AM
#356   Thanks for that article. backtrax 11/19/10 03:34:36 PM
#355   Bloomberg Interview: Lequn Lee Huang GorillaGorilla 11/17/10 10:11:50 AM
#354   I also like that eps were up in pappy 11/06/10 06:25:54 PM
#353   10 Q out....gains in cash and assets. backtrax 10/21/10 10:55:29 AM
#352   1st qtr number should be any time now pappy 10/07/10 03:58:10 PM
#351   I think we were talking about EPS not dividends. GorillaGorilla 10/04/10 04:41:53 AM
Consent Preferences